Literature DB >> 8683639

Typhlitis associated with docetaxel treatment.

F Cardenal, A Montes, G Llort, J Seguí, R Mesía.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683639     DOI: 10.1093/jnci/88.15.1078

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  6 in total

Review 1.  Systematic review of case reports concerning adults suffering from neutropenic enterocolitis.

Authors:  Andrés Felipe Cardona Zorrilla; Ludovic Reveiz Herault; Alexandra Casasbuenas; Diego Mauricio Aponte; Pedro Luis Ramos
Journal:  Clin Transl Oncol       Date:  2006-01       Impact factor: 3.405

2.  Neutropenia and enterocolitis with docetaxel treatment.

Authors:  Alberto Ocaña Fernández; Ignacio Martín González; Amalia Gómez Bernal; Juan Jesús Cruz Hernández
Journal:  Clin Transl Oncol       Date:  2005-03       Impact factor: 3.405

Review 3.  Necrotizing enterocolitis in neutropenia and chemotherapy: a clinical update and old lessons relearned.

Authors:  CelesteAnn T Bremer; Brian P Monahan
Journal:  Curr Gastroenterol Rep       Date:  2006-08

Review 4.  Risks and benefits of taxanes in breast and ovarian cancer.

Authors:  L B Michaud; V Valero; G Hortobagyi
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

5.  Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer.

Authors:  X Garcia del Muro; E Marcuello; J Gumá; L Paz-Ares; M A Climent; J Carles; M Sánchez Parra; J L Tisaire; P Maroto; J R Germá
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

6.  Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire breast cancer research group study.

Authors:  A C Humphreys; J Dent; S Rodwell; S M Crawford; J K Joffe; C Bradley; D Dodwell; T J Perren
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.